Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.37)
# 236
Out of 4,829 analysts
81
Total ratings
54.39%
Success rate
17.47%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $24.25 | +31.96% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $115.71 | +59.88% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $23.96 | +25.21% | 1 | Mar 12, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $46.26 | +40.51% | 2 | Feb 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $34.17 | +46.33% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $14.58 | +242.94% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $92.87 | +34.60% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $58.86 | +78.39% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $527.78 | +122.63% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $57.55 | +47.70% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $35.11 | +150.64% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $118.17 | +133.56% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $1.82 | +1,823.08% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,520 → $780 | $3.50 | +22,185.71% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $265.86 | -12.74% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $58.98 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $96.91 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $30.13 | -30.30% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $2.91 | +690.38% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.41 | +2,556.75% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.70 | +1,326.53% | 1 | Feb 14, 2018 |
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $24.25
Upside: +31.96%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $115.71
Upside: +59.88%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $23.96
Upside: +25.21%
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $46.26
Upside: +40.51%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $34.17
Upside: +46.33%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $14.58
Upside: +242.94%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $92.87
Upside: +34.60%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $58.86
Upside: +78.39%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $527.78
Upside: +122.63%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $57.55
Upside: +47.70%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $35.11
Upside: +150.64%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $118.17
Upside: +133.56%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $1.82
Upside: +1,823.08%
Feb 17, 2021
Downgrades: Neutral
Price Target: $1,520 → $780
Current: $3.50
Upside: +22,185.71%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $265.86
Upside: -12.74%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $58.98
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $96.91
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $30.13
Upside: -30.30%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $2.91
Upside: +690.38%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.41
Upside: +2,556.75%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.70
Upside: +1,326.53%